Abbott's Kaletra Promotions Overstate Length Of Efficacy, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
A poster and print ad for the protease inhibitor combo make the unsubstantiated claim that patients taking Kaletra "can expect to survive and be healthy" for five years, FDA says. Abbott releases six-year Kaletra data at ICAAC conference.
You may also be interested in...
Enbrel TV Ad Highlighting "Breakthrough Therapy" Draws FDA Warning Letter
Center for Drug Evaluation & Research ad review division says Amgen's commercial overstates the TNF-inhibitor's effectiveness, fails to communicate the limitations of the indication and minimizes risk. Amgen pulls the commercial from its media schedule in the wake of the agency's letter.
Enbrel TV Ad Highlighting "Breakthrough Therapy" Draws FDA Warning Letter
Center for Drug Evaluation & Research ad review division says Amgen's commercial overstates the TNF-inhibitor's effectiveness, fails to communicate the limitations of the indication and minimizes risk. Amgen pulls the commercial from its media schedule in the wake of the agency's letter.
Norvir Exclusivity Is Safe; NIH Says "March-In" Test Is Availability, Not Price
Abbott has met the requirements of the Bayh/Dole Act, NIH declares. "March-in" rights are not the right way to address drug pricing, agency says: that is up to Congress.